CCIA
CNTA

Campbell & Co Investment Adviser’s Centessa Pharmaceuticals CNTA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,243
Closed -$406K – 1125
2025
Q4 		$406K Sell
16,243
-9,602
-37% -$243K 0.02% 895
2025
Q3 		$627K Buy
25,845
+9,226
+56% +$164K 0.05% 627
2025
Q2 		$218K Buy
+16,619
New +$211K 0.01% 1041

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Campbell & Co Investment Adviser's CNTA Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 16,243 shares — an estimated $406K sold.

Campbell & Co Investment Adviser first reported a position in CNTA in Q2 2025 and held it in 3 quarters. The position peaked at $627K in Q3 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 16,243 Centessa Pharmaceuticals shares in Q1 2026, an estimated $406K.
  • Campbell & Co Investment Adviser first reported a position in Centessa Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Centessa Pharmaceuticals position peaked at $627K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.